Formats
  1. Journal Article (66894)
  2. Meeting Abstract (33621)
  3. Book Section (5097)
  4. Review (3749)
  5. Editorial (2165)
  6. Conference Paper (1526)
  7. Correspondence (663)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Book Whole (344)
  11. Miscellaneous (339)
Groups
  1. Department of Medicine (39043)
  2. GSK Faculty (22462)
  3. Solid Tumor Oncology Division (22061)
  4. Surgery (21262)
  5. Survivorship Research (15766)
  6. Sloan Kettering Institute Faculty (15652)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (2139)
  2. 2024 (5384)
  3. 2023 (5806)
  4. 2022 (6169)
  5. 2021 (5714)
  6. 2020 (5618)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4951)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2611)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1814)

More Publications

Publishers
  1. Elsevier Inc. (13846)
  2. American Society of Clinical Oncology (9169)
  3. Springer (7192)
  4. Nature Publishing Group (6375)
  5. American Association for Cancer Research (6014)
  6. Elsevier Science, Inc. (5512)

More Publishers

Results (115607)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 3 trial of subcutaneous epcoritamab in combination with rituximab and lenalidomide (R(2)) vs R(2) among patients with relapsed or refractory follicular lymphoma (EPCORE FL-1)
    Meeting Abstract

    Falchi, L.; Morschhauser, F.; Gribben, J. G.; Huang, H.; Dinh, M.; Conlon, R.; Chen, X.; Elliot, B.; Seymour, J. F.
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed / refractory mantle cell lymphoma: Additional patients and extended follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Gerson, J. N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Erythroid and megakaryocytic differentiation program in JAK2-mutated acute myeloid leukemia with or without antecedent myeloproliferative neoplasm
    Meeting Abstract

    Liu, Y.; Sethi, S.; Koche, R.; Gao, Q.; Dilip, D.; Glass, J. L.; Galera, P. K.; Persaud, S.; Mishra, T.; Sun, X.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Whole genome sequencing comparison of acute myeloid leukemia at presentation and remission predicts patient outcome
    Meeting Abstract

    Moffitt, A. B.; Alexander, J.; Stepansky, A.; Famulare, C.; Lopez, C. A.; Hakim, N.; Wu, V.; Wang, Z.; Kolitz, J. E.; Chiorazzi, N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • BCL6-mediated escape from negative selection enables RAS-driven B-cell transformation
    Meeting Abstract

    Chan, L. N.; Hurtz, C.; Robinson, M. E.; Leveille, E.; Geng, H.; Caeser, R.; Xu, L.; Kume, K.; Xiao, G.; Müschen, M.
    Blood (2022)

    Fulltext@MSK | Save
  • Correlative biomarkers for CART19 response in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Batlevi, C. L.; Nos, G.; Kotlov, N.; Sorokina, M.; Okwali, M.; Bagaev, A.; Michaud, L.; Shah, G. L.; Shouval, R.; Tomas, A. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A Phase 1b dose escalation and expansion study of SNDX-5613, azacitidine (AZA) and venetoclax (VEN) in newly diagnosed, patients ≥ 60 years with untreated NPM1-mutated/ FLT3-wild type AML or KMT2A-rearranged acute myeloid leukemia (AML)
    Meeting Abstract

    Zeidner, J. F.; Foster, M. C.; Johnson, M.; Huang, Y.; Swords, R. T.; Stein, E.; Foran, J. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A multi-center phase Ib trial of the histone deactylase inhibitor (HDACi) entinostat in combination with anti-pd1 antibody pembrolizumab in patients with refractory/relapsed myelodysplastic syndromes (RR-MDS) or oligoblastic acute myeloid leukemia (RR-AML) after hypomethylating agent (HMA) failure
    Meeting Abstract

    Bewersdorf, J. P.; Shallis, R. M.; Sharon, E.; Caldwell, A.; Wei, W.; Yacoub, A.; Madanat, Y. F.; Zeidner, J. F.; Altman, J. K.; Odenike, O.; more...
    Blood (2022)

    Fulltext@MSK | Save